October 25, 2010 - A post-hoc-analysis from JUPITER, published in the European Heart Journal, shows rosuvastatin (Crestor) significantly reduced major cardiovascular (CV) events, compared to placebo in high risk patients. The risk reductions observed in this patient population were consistent with those seen in the primary JUPITER analysis.
